Eli Lilly has deepened its push into artificial intelligence-driven drug development, agreeing a global licensing and research deal worth up to $2.75 billion with Hong Kong-listed Insilico Medicine in one of the largest AI-focused collaborations yet in the pharmaceutical industry.
The agreement gives Lilly exclusive rights to develop, manufacture, and commercialize selected preclinical oral drug candidates developed by Insilico using generative AI tools. Under the terms, Insilico will receive $115 million upfront, with the remaining value tied to development, regulatory, and commercial milestones, alongside tiered royalties on future sales.
The size of the deal underscores how major drugmakers are increasingly moving beyond experimental AI pilots and committing serious capital to machine-learning-led drug discovery platforms.
Register for Tekedia Mini-MBA edition 20 (June 8 – Sept 5, 2026).
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab.
At its core, the partnership is a bet on speed and efficiency. Traditional drug discovery can take three to six years in the preclinical phase alone, often requiring the screening and testing of thousands of compounds. Insilico says its AI platform has significantly compressed that timeline, reducing candidate nomination to roughly 12 to 18 months in some programmes.
That acceleration is becoming increasingly valuable for large pharmaceutical companies facing rising R&D costs, patent cliffs, and intense competition in high-growth therapeutic areas such as obesity, diabetes, oncology, and immunology.
Insilico founder and chief executive Alex Zhavoronkov said the company has developed at least 28 drug candidates using generative AI systems, with nearly half already in clinical development. That clinical conversion rate is likely one of the key factors behind Lilly’s decision to deepen its partnership.
This is not the first collaboration between the two companies. Lilly and Insilico have worked together since 2023 under a software licensing agreement focused on AI-based discovery tools. The new arrangement expands that relationship from software access to a full-scale licensing and research partnership, signaling growing confidence in the platform’s scientific and commercial potential.
The move also fits into a broader repositioning by Lilly as it seeks to remain at the forefront of pharmaceutical innovation.
The company has been aggressively investing in AI infrastructure and partnerships. Earlier this year, it announced a major collaboration with Nvidia aimed at accelerating computational drug development, highlighting how AI is becoming central to its long-term research model.
Lilly already dominates fast-growing markets through blockbuster diabetes and obesity drugs, making the commercial rationale clear. Adding AI-generated molecules to its pipeline offers a way to diversify beyond existing franchises and sustain long-term growth.
There is also a geopolitical dimension to the transaction. The deal comes shortly after Lilly chief executive David Ricks attended a high-level forum in Beijing and weeks after the company unveiled plans to invest $3 billion in China over the next decade. While China currently contributes less than 3% of Lilly’s annual revenue, the market remains strategically important both as a growth opportunity and as a research ecosystem.
Insilico’s operating model reflects this cross-border dynamic. While its AI research and model development are conducted largely outside mainland China, including in Canada and the Middle East, early-stage preclinical work is carried out in China, where costs and development cycles can be more competitive.
The partnership also comes as the pharmaceutical industry increasingly turns to AI not merely as a productivity tool but as a fundamental scientific engine. Drugmakers are under pressure to shorten development cycles, improve success rates, and reduce reliance on animal testing, in line with evolving regulatory expectations from agencies including the U.S. Food and Drug Administration.
The significance of the deal lies not only in its headline value but in what it signals for the future of medicine.
This is one of the clearest indications yet that AI-designed molecules are moving from concept to commercial reality, with big pharma now willing to place multibillion-dollar bets on the technology’s ability to produce viable therapies. If even one of the licensed candidates advances successfully through clinical trials and reaches market, it could reshape how the industry approaches drug discovery for years to come.